Abstract:Background: The basket trial evaluates the treatment effect of a targeted therapy in patients with the same genetic or molecular aberration, regardless of their cancer types. Bayesian hierarchical modeling has been proposed to adaptively borrow information across cancer types to improve the statistical power of basket trials. Although conceptually attractive, research has shown that Bayesian hierarchical models cannot appropriately determine the degree of information borrowing and may lead to substantially inflated type I error rates. Methods: We propose a novel calibrated Bayesian hierarchical model approach to evaluate the treatment effect in basket trials. In our approach, the shrinkage parameter that controls information borrowing is not regarded as an unknown parameter. Instead, it is defined as a function of a similarity measure of the treatment effect across tumor subgroups. The key is that the function is calibrated using simulation such that information is strongly borrowed across subgroups if their treatment effects are similar and barely borrowed if the treatment effects are heterogeneous. Results: The simulation study shows that our method has substantially better controlled type I error rates than the Bayesian hierarchical model. In some scenarios, for example, when the true response rate is between the null and alternative, the type I error rate of the proposed method can be inflated from 10% up to 20%, but is still better than that of the Bayesian hierarchical model. Limitation: The proposed design assumes a binary endpoint. Extension of the proposed design to ordinal and time-to-event endpoints is worthy of further investigation. Conclusion: The calibrated Bayesian hierarchical model provides a practical approach to design basket trials with more flexibility and better controlled type I error rates than the Bayesian hierarchical model. The software for implementing the proposed design is available at http://odin.mdacc.tmc.edu/~yyuan/index_code.html

A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes.

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

BLAST: Bayesian Latent Subgroup Design for Basket Trials Accounting for Patient Heterogeneity

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies.

TITE‐BOIN12: A Bayesian Phase I/II Trial Design to Find the Optimal Biological Dose with Late‐onset Toxicity and Efficacy

A Bayesian Dose-Finding Design for Phase I/II Clinical Trials with Nonignorable Dropouts.

A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints.

Bayesian hybrid dose-finding design in phase I oncology clinical trials.

A Bayesian Phase I/II Trial Design for Immunotherapy

Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN).

Bayesian Phase II Adaptive Randomization by Jointly Modeling Time-to-event Efficacy and Binary Toxicity

Statistical Tutorial for Using Bayesian Optimal Interval (BOIN) Design for Phase I Single-Agent and Drug-Combination Trials

A Bayesian Phase II Proof-of-concept Design for Clinical Trials with Longitudinal Endpoints.

BOP2: Bayesian Optimal Design for Phase II Clinical Trials with Simple and Complex Endpoints.

Optimal Bayesian Hierarchical Model to Accelerate the Development of Tissue-Agnostic Drugs and Basket Trials.

A Utility‐based Bayesian Optimal Interval (U‐BOIN) Phase I/II Design to Identify the Optimal Biological Dose for Targeted and Immune Therapies

Phase I Trial Design for Drug Combinations with Bayesian Model Averaging.

Bayesian Optimal Phase II Design for Randomized Clinical Trials

A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints

A Bayesian Basket Trial Design Using a Calibrated Bayesian Hierarchical Model